Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Debt: 2010-2025

Historic Total Debt for Arrowhead Pharmaceuticals (ARWR) over the last 9 years, with Sep 2025 value amounting to $254.9 million.

  • Arrowhead Pharmaceuticals' Total Debt fell 35.17% to $254.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.9 million, marking a year-over-year decrease of 35.17%. This contributed to the annual value of $254.9 million for FY2025, which is 35.17% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Total Debt stood at $254.9 million for Q3 2025, which was up 6.05% from $240.3 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' Total Debt's 5-year high stood at $409.4 million during Q4 2024, with a 5-year trough of $240.3 million in Q2 2025.
  • Its 2-year average for Total Debt is $314.3 million, with a median of $273.9 million in 2025.
  • Data for Arrowhead Pharmaceuticals' Total Debt shows a maximum YoY tumbled of 35.17% (in 2025) over the last 5 years.
  • Arrowhead Pharmaceuticals' Total Debt (Quarterly) stood at $409.4 million in 2024, then tumbled by 35.17% to $254.9 million in 2025.
  • Its Total Debt was $254.9 million in Q3 2025, compared to $240.3 million in Q2 2025 and $273.9 million in Q1 2025.